120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
穴位埋线治疗多囊卵巢综合征相关肥胖的有效性和安全性：定性与定量分析
Authors Li XX, Hu ZY, Yuan DN, Zhao JX, Ma WB , Lan L
Received 15 July 2025
Accepted for publication 26 January 2026
Published 21 February 2026 Volume 2026:19 553787
DOI https://doi.org/10.2147/DMSO.S553787
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Liang Wang
Xing-xian Li,1 Zhuo-ya Hu,1 Dong-ni Yuan,1 Jun-xin Zhao,1 Wen-bin Ma,2 Lei Lan1
1Acupuncture and Tuina College, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
Correspondence: Lei Lan, Email lanlei@cdutcm.edu.cn
Aim: Obesity is common in women with polycystic ovary syndrome (PCOS) and can exacerbate PCOS symptoms. Although Acupoint catgut embedding (ACE) is frequently used to treat the clinical symptoms of simple obesity, it is unclear how it will affect obesity associated with PCOS. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) to evaluate the effectiveness of ACE in treating obesity in women with PCOS.
Methods: We searched databases from inception to January 8, 2025. Two independent reviewers extracted data and assessed the risk of bias. All meta-analyses used random effects models, and the GRADE approach was used to assess the certainty of the evidence.
Results: We included 25 RCTs (1,663 participants). Based on usual care, compared to blank treatment, ACE probably reduces body mass index (BMI), waist-to-hip ratio (WHR), and waist circumference (WC), and may enable a greater proportion of patients to achieve a weight loss no less than 5% (relative risk [RR] 1.33, 95% CI 1.15 to 1.55) and may reduce triglycerides (TG). Furthermore, when compared to active comparators, ACE probably enables a greater proportion of patients to achieve a weight loss no less than 5% (RR 1.40, 95% CI 1.11 to 1.76) and reduces WC and may also reduce BMI and TG. All effects were supported by low to moderate certainty evidence.
Conclusion: When compared to blank treatment, on the basis of usual care, ACE for obesity associated with PCOS may improve obesity-related outcomes. When compared to active comparators, it may have comparable or greater therapeutic efficacy and fewer adverse events. Such improvements in obesity-related indicators may help alleviate metabolic and reproductive symptoms in women with PCOS. As all included trials were conducted in China, further high-quality studies in diverse populations are needed to confirm the generalizability of these findings.
Keywords: obesity, polycystic ovary syndrome, acupoint catgut embedding, meta-analysis
1Acupuncture and Tuina College, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China
Correspondence: Lei Lan, Email lanlei@cdutcm.edu.cn
Aim: Obesity is common in women with polycystic ovary syndrome (PCOS) and can exacerbate PCOS symptoms. Although Acupoint catgut embedding (ACE) is frequently used to treat the clinical symptoms of simple obesity, it is unclear how it will affect obesity associated with PCOS. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) to evaluate the effectiveness of ACE in treating obesity in women with PCOS.
Methods: We searched databases from inception to January 8, 2025. Two independent reviewers extracted data and assessed the risk of bias. All meta-analyses used random effects models, and the GRADE approach was used to assess the certainty of the evidence.
Results: We included 25 RCTs (1,663 participants). Based on usual care, compared to blank treatment, ACE probably reduces body mass index (BMI), waist-to-hip ratio (WHR), and waist circumference (WC), and may enable a greater proportion of patients to achieve a weight loss no less than 5% (relative risk [RR] 1.33, 95% CI 1.15 to 1.55) and may reduce triglycerides (TG). Furthermore, when compared to active comparators, ACE probably enables a greater proportion of patients to achieve a weight loss no less than 5% (RR 1.40, 95% CI 1.11 to 1.76) and reduces WC and may also reduce BMI and TG. All effects were supported by low to moderate certainty evidence.
Conclusion: When compared to blank treatment, on the basis of usual care, ACE for obesity associated with PCOS may improve obesity-related outcomes. When compared to active comparators, it may have comparable or greater therapeutic efficacy and fewer adverse events. Such improvements in obesity-related indicators may help alleviate metabolic and reproductive symptoms in women with PCOS. As all included trials were conducted in China, further high-quality studies in diverse populations are needed to confirm the generalizability of these findings.
Keywords: obesity, polycystic ovary syndrome, acupoint catgut embedding, meta-analysis